Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Effects of subcutaneous interleukin-2 therapy on phenotype and function ofperipheral blood mononuclear cells in human immunodeficiency virus infected patients
Autore:
Aladdin, H; Larsen, CS; Moller, BK; Ullum, H; Buhl, MR; Gerstoft, J; Skinhoj, P; Pedersen, BK;
Indirizzi:
Rigshosp, Epidemiafdeling M7641, Dept Infect Dis, DK-2200 Copenhagen N, Denmark Rigshosp Copenhagen Denmark N Infect Dis, DK-2200 Copenhagen N, Denmark Marselisborg Hosp, Dept Med & Infect Dis, Aarhus, Denmark Marselisborg Hosp Aarhus Denmark Dept Med & Infect Dis, Aarhus, Denmark
Titolo Testata:
SCANDINAVIAN JOURNAL OF IMMUNOLOGY
fascicolo: 2, volume: 51, anno: 2000,
pagine: 168 - 175
SICI:
0300-9475(200002)51:2<168:EOSITO>2.0.ZU;2-A
Fonte:
ISI
Lingua:
ENG
Soggetto:
HIV-1 SEROPOSITIVE INDIVIDUALS; IMMUNE-DEFICIENCY SYNDROME; AIDS-RELATED COMPLEX; T-LYMPHOCYTES; RECOMBINANT INTERLEUKIN-2; DISEASE PROGRESSION; TYPE-1 INFECTION; DENDRITIC CELLS; HOMOSEXUAL MEN; KILLER-CELLS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
42
Recensione:
Indirizzi per estratti:
Indirizzo: Aladdin, H Rigshosp, Epidemiafdeling M7641, Dept Infect Dis, Tagensvej 20,DK-2200 Copenhagen N, Denmark Rigshosp Tagensvej 20 Copenhagen Denmark N penhagen N, Denmark
Citazione:
H. Aladdin et al., "Effects of subcutaneous interleukin-2 therapy on phenotype and function ofperipheral blood mononuclear cells in human immunodeficiency virus infected patients", SC J IMMUN, 51(2), 2000, pp. 168-175

Abstract

In the context of clinical therapy with recombinant human interleukin-2 (IL-2), we monitored immunological alteration in 10 human immunodeficiency virus type-1 (HIV-1)-infected individuals, on stable antiretroviral therapy, who had a CD4(+) cell count between 200 and 500 cells/mm(3). Subcutaneous IL-2 was prescribed thrice weekly (at a dose of 3 x 10(6) IU) for 24 weeks and the patients were followed-up for 32 weeks. IL-2 treatment induced an increase in the CD4(+) percentage (P < 0.001) and CD4(+) cell count (P < 0.009). Furthermore, natural killer (NK) cell activity was increased (P < 0.001) at week 8 of treatment, whereas lymphokine-activated killer (LAK) cell activity showed a transient, nonsignificant increase at week 8 and was reduced (P < 0.001) at 32 weeks. However, the cytotoxic T-lymphocyte (CTL) activity decreased against HIV antigens, and the proliferative response to Candida, IL-2 and phytohaemagglutinin (PHA) declined during the first 8 weeks (P < 0.05) and returned to baseline levels after 32 weeks. The HIV RNA level did not change during IL-2 therapy; however, after 8 weeks of follow-up a significant increase (P < 0.001) in viral load was observed. In conclusion, continuous IL-2 treatment to HIV-infected individuals enhanced the CD4 count, but the in vitro lymphocyte function was impaired and an increase in viral replication occurred after treatment.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 16/07/20 alle ore 17:44:30